Market Overview

UPDATE: Canaccord Genuity Initiates Synageva BioPharma at Buy, $60 PT; Attractive Orphan Platform

Share:
Related GEVA
Synageva BioPharma Announces Dosing Of Patients Commenced With SBC-103 In Phase 1/2 Study For Mucopolysaccharidosis IIIB And FDA Fast Track Designation Granted
Clear Channel Outdoor, Oasis Petroleum And Other Insiders Have Been Buying

Canaccord Genuity initiates its coverage on Synageva BioPharma (NASDAQ: GEVA) with a Buy rating and a price target of $90.

Canaccord Genuity says, "Early but encouraging SBC--102 proof --102 proof--of --of- ofof-concept data: --concept data: The lateonset LAL-D Phase 1/2 trial data presented to date has been impressive – rapid and significant decreases in hepatic enzymes indicate that SBC-102 is having the predicted biochemical role in combating liver abnormalities."

GEVA closed at $38.50 on Friday.

Latest Ratings for GEVA

DateFirmActionFromTo
Oct 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014CitigroupInitiates Coverage onNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for GEVA
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Initiation Pre-Market Outlook Analyst Ratings

 

Related Articles (GEVA)

Around the Web, We're Loving...

Get Benzinga's Newsletters